Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat

American Journal of Nephrology

Volumn 30, Issue 4, 2009, Pages 354-360

  Whaley Connell, Adam ^a,b,d   Habibi, Javad ^a,b,d   Johnson, Megan ^a,b   Tilmon, Roger ^a,b   Rehmer, Nathan ^a,b   Rehmer, Jenna ^a,b   Wiedmeyer, Charles ^c   Ferrario, Carlos M ^e   Sowers, James R ^a,b,d  

^a University of Missouri   (United States)

^b Diabetes and Cardiovascular Center   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

NADPH oxidase; Nebivolol; Proteinuria; Reactive oxygen species

Indexed keywords

3 NITROTYROSINE; NEBIVOLOL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; KIDNEY CORTEX; KIDNEY INJURY; NONHUMAN; OSMOTIC MINIPUMP; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; TRANSGENIC ANIMAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ETHANOLAMINES; HYPERTENSION, RENAL; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; REACTIVE OXYGEN SPECIES; RENIN; RENIN-ANGIOTENSIN SYSTEM; TYROSINE;

EID: 67650457594     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229305     Document Type: Article

References (30)

1. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501. (Pubitemid 30165039)
2. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-252.
3. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GME, Clark SE, Stump CS, Ferrario CM, Sowers JR: NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391. (Pubitemid 47205789)
4. Griendling KK, Murphy TJ, Alexander RW: Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.
5. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Link D, Karuparthi PR, Stump C, Ferrario C, Sowers JR: Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 2007; 293:E355-E363.
6. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR: Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293:H2009-H2023. (Pubitemid 47605846)
7. O'Donnell VB, Freeman BA: Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res 2001; 88: 12-21. (Pubitemid 32064077)
8. Kakoki M, Hirata Y, Hayakawa H, Suzuki E, Nagata D, Nishimatsu H, Kimura K, Goto A, Omata M: Effects of vasodilatory antihypertensive agents on endothelial dysfunction in rats with ischemic acute renal failure. Hypertens Res 2000; 23: 527-533. (Pubitemid 30742127)
9. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, Todeschini M, Remuzzi G: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 1999; 33: 746-753. (Pubitemid 29159943)
10. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-2752. (Pubitemid 36667251)
11. Klahr S, Morrissey J: L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 2004; 24: 389-394. (Pubitemid 38900638)
12. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D: The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharm 2005;508: 159-166. (Pubitemid 40169915)
13. Pires MJ, Rodríguez-Peña AB, Arévalo M, Cenador B, Evangelista S, Esteller A, Sánchez-Rodríguez A, Colaço A, López-Novoa JM: Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007; 25: 2486-2489.
14. Gupta S, Wright HM: Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26: 189-202.
15. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L: Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-596. (Pubitemid 40684718)
16. Van de Water A, Janssens W, Neuten JV, Xhonneux R, Cree JD, Verhaegen H: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-563. (Pubitemid 18128104)
17. Bowman AJ, Chen CP, Ford GA: Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204. (Pubitemid 24282739)
18. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-514. (Pubitemid 32738117)
19. Bristow MR, Nelson P, Minobe W, Johnson C: Characterization of [beta]1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hyperten 2005; 18:A51-A52.
20. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, Rehmer N, DeMarco VG, Andresen BT, Wei Y, Ferrario C, Sowers JR: Attenuation of angiotensin II-mediated NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008; 51: 474-480. (Pubitemid 351156435)
21. Hayden MR, Whaley-Connell A, Sowers JR: Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy. Am J Nephrol 2005; 25: 553-569.
22. Whaley-Connell A, Chowdhury N, Hayden MR, Stump CS, Habibi J, Wiedmeyer C, Gallagher PE, Tallant A, Cooper SA, Link CD, Ferrario C, Sowers JR: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006; 291:F1308-F1314. (Pubitemid 44887244)
23. Morris EM, Whaley-Connell A, Thyfault JP, Britton SL, Lock LG, Wei Y, Ibdah JI, Sowers JR: Low aerobic capacity and high fat diet contributes to oxidative stress and IRS-1 degradation in the kidney. Am J Nephrol 2008; 30: 112-119.
24. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR: Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009; 296: F1013-F1022.
25. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators: Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46: 1309-1315. (Pubitemid 43189728)
26. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-684. (Pubitemid 44843872)
27. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, Wendt M, Walter U, Geiger C, Agrawal R, Kleschyov AL, Meinertz T, Münzel T: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23: 615-621. (Pubitemid 36438074)
28. Weber MA: The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18: 169S-176S.
29. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424. (Pubitemid 46217686)
30. Nistala R, Whaley-Connell A, Sowers JR: Redox control of renal function and hypertension. Antioxid Redox Signal 2008; 10: 2047-2089.